Tyrosine kinase inhibitors (TKIs) are already available, such as the Novartis drugs Scemblix and Gleevec. But CML can become resistant to these therapies, Ascentage said in its IPO filing.
One study conducted in Thailand compared the effectiveness of PILs to traditional package inserts (PIs) in enhancing patients' medication safety knowledge. The findings revealed that patients who ...